Truist Financial analyst David S Macdonald maintained a Buy rating on Guardian Pharmacy Services, Inc. Class A (GRDN – Research Report) today.

Guardian Pharmacy sees FY25 revenue $1.33B-$1.35B, consensus $1.33B Sees FY25 adjusted EBITDA $97M-$101M. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Try Now>> See the top stocks recommended by analysts >> Guardian Pharmacy Services NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Monday said that Q4 revenue is expected to be about $338.6 million, an increase of about 20.5% year-over-year.

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s largest long-term care (LTC) pharmacy services companies, today announced that they will participate ...

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United ...

Guardian Pharmacy Services is a leading long-term care pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care ...

Allspring Global Investments Holdings LLC reduced its stake in Guardian Pharmacy Services, Inc. (NYSE:GRDN – Free Report) by 2.2% during the 4th quarter, according to the company in its most ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edgewise Therapeutics (EWTX – Research Report) and Walgreens ...

Lawyers for filmmaker Noel Clarke told a court today that The Guardian newspaper acted as the “judge, jury, and executioner” of the Kidulthood filmmaker’s career when they published a series ...